Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss
Abstract Background/Aims It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy. This study aims to investigate the role of NUCs continuation in HBsAg seroreversion. Methods Patients w...
Saved in:
| Main Authors: | Na Gao, Haishi Wu, Bin Li, Huiying Yu, Lili Wu, Jing Zhang, Nan Zhang, Bingliang Lin, Qiyi Zhao, Zhiliang Gao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12985-025-02700-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment
by: Jian Wang, et al.
Published: (2025-08-01) -
Concurrent presence of HBsAg and anti-HBs in children
by: H Ozen, et al.
Published: (2000-07-01) -
Efficacy of extracorporeal immunoadsorption therapy for removal of HBsAg
by: Meng Wang, et al.
Published: (2025-07-01) -
HBsAg and anti-HBs coexistence in patients with HBV in acute and chronic phases
by: Zhongshu Pu, et al.
Published: (2025-05-01) -
Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia
by: Lilin Wang, et al.
Published: (2025-08-01)